Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in advanced biliary tract cancer
NCT03101566Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in biliary tract cancer (BTC), sponsored by University of Michigan Rogel Cancer Center. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03101566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101566.